Skip to main content
Clinical Trials/NCT02453698
NCT02453698
Completed
Phase 1

Stimulant Effects on Brain Activity During the Stop Signal Task

The Hospital for Sick Children1 site in 1 country19 target enrollmentJanuary 2011

Overview

Phase
Phase 1
Intervention
Methylphenidate
Conditions
Healthy Volunteers
Sponsor
The Hospital for Sick Children
Enrollment
19
Locations
1
Primary Endpoint
Neural activity assessed using fMRI
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

The aim of this study is to investigate the effects of Methylphenidate on neural activity underlying inhibitory control and error monitoring in healthy adults. More specifically, the investigators aim to establish the baseline modulatory effect of Mehtlylphenidate on bottom-up and top-down aspects of these cognitive processes. This work will further our understanding of Attention Deficit Hyperactivity Disorder, Methylphenidate, and executive functioning.

Detailed Description

Methylphenidate (MPH) is the stimulant medication most commonly used in the treatment of attention deficit hyperactivity disorder (ADHD). MPH suppresses the reuptake of dopamine by blocking dopamine transporter, which is elevated in ADHD. However, the precise mechanism by which suppressed dopamine transporter activity relieves ADHD symptoms is not fully understood, partly because dopamine pathways are implicated in various processes that could play a role in the deficits of ADHD and other disorders. MPH-induced dopamine variation has extensive effects in the brain and influences various executive functions in unknown ways. Hypotheses: Inhibitory Control: The investigators predict that MPH should increase the top-down activity in right dorsolateral prefrontal cortex associated with response restraint during go-phases and bottom-up activity in caudate and right inferior frontal cortex associated with response cancellation during successful stop trials. A greater modulation of top-down or bottom-up activity would imply a selective effect of MPH on one pathway over the other. Error Processing: The investigators predict that MPH should increase the intensity of deactivation in the bottom-up dopamine pathway on error detection (substantia nigra, dorsal striatum and ACC), and increase the intensity of deactivation in the top-down pathway on post-error slowing (caudal OFC, ventral striatum, ventral substantia nigra). A greater modulation of top-down or bottom-up activity would imply a selective effect of MPH on one pathway over the other.

Registry
clinicaltrials.gov
Start Date
January 2011
End Date
March 2012
Last Updated
10 years ago
Study Type
Interventional
Study Design
Crossover
Sex
Male

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Russell Schachar

Staff Physician

The Hospital for Sick Children

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

Methylphenidate

Intervention: Methylphenidate

Control Group

Intervention: Placebo

Outcomes

Primary Outcomes

Neural activity assessed using fMRI

Time Frame: 7 days

Assessed using fMRI

Study Sites (1)

Loading locations...

Similar Trials